Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myosin light chain kinase 3 (MYLK3)
- Target
- MYLK3
- Molecular classification
- Enzyme, Protein kinase (serine/threonine kinase), Calmodulin-dependent kinase
01
Overview
Myosin light chain kinase 3 (MYLK3) is a cardiac-specific serine/threonine protein kinase that phosphorylates myosin regulatory light chain 2 (MLC2) in a calcium/calmodulin-dependent manner, potentiating force generation and contractility in cardiac myocytes[1][2][4][5]. Expression of MYLK3 is highly specific to the heart, and it plays a central role in sarcomere organization and normal cardiac muscle function[5]. Mutations in the MYLK3 gene disrupt MLC2 phosphorylation and have been linked to familial dilated cardiomyopathy, emphasizing its critical role in cardiac health[3][5]. There are currently no approved drugs directly targeting MYLK3, and its modulation is associated with potential cardiac safety concerns due to its essential function in myocardial contractility and structure[3][5].
- Other names
- MLCKcardiac-MLCKcaMLCKcardiac-MyBP-C-associated Ca/CaM kinaseMLC kinaseMLCK2putative myosin light chain kinase 3
02
Biological functions
Phosphorylation of cardiac myosin light chain 2 (MLC2)Regulation of cardiac muscle contractionPromotion of sarcomere formation in cardiomyocytesRegulation of actin−myosin interactionsEnhancement of contractile force in heart muscle
03
Disease associations
Cardiovascular diseaseDilated cardiomyopathyHeart failure
04
Safety considerations
Loss-of-function mutations associated with cardiac dysfunction and heart failure[3]Instability of mutant protein leading to reduced kinase activity, potentially contributing to cardiomyopathy[3]
05
Biomarkers
MYLK3 gene mutations (as biomarkers for familial dilated cardiomyopathy)[3]Reduced phosphorylation of cardiac myosin light chain 2 (MLC2)[3][5]
Beyond the preview
Go deeper on Myosin light chain kinase 3 (MYLK3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myosin light chain kinase 3 (MYLK3).